<DOC>
	<DOCNO>NCT01019668</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness well detrimental influence half-dose half-fluence modification verteporfin photodynamic therapy ( PDT ) treatment prolong unresolved central serous chorioretinopathy ( CSCR ) .</brief_summary>
	<brief_title>Central Serous Chorioretinopathy Treated Modified Photodynamic Therapy</brief_title>
	<detailed_description>Purpose : evaluate effectiveness well detrimental influence half-dose half-fluence modification verteporfin PDT treatment prolong unresolved Central Serous Chorioretinopathy ( CSCR ) . Study Design Patient Recruitment : This study prospective , randomize , consecutive , open-labeled , comparative interventional case series . Patients symptomatic acute chronic CSC 3 week duration recruit . Patients offer treatment worsen symptom subjective improvement since onset CSC . Inclusion criterion include 1 ) patient best-corrected visual acuity ( BCVA ) 20/400 good ; 2 ) presence subretinal fluid ( SRF ) and/or serous pigment epithelial detachment ( PED ) involve fovea optical coherence tomography ( OCT ) ; 3 ) presence active angiographic leakage fluorescein angiography ( FA ) cause CSC CNV diseases ; 4 ) abnormal dilate choroidal vasculature feature ICGA consistent diagnosis CSC . Patients receive previous PDT focal thermal laser photocoagulation treatment CSC evidence CNV , polypoidal choroidal vasculopathy , maculopathy clinical examination , FA , ICGA exclude . Informed consent obtain subject . 12 patient group plan recruit group . Modified Photodynamic Therapy Half Dosage : The Half Dosage PDT protocol CSC perform use half normal dose verteporfin ( Visudyne , Novartis AG , Bülach , Switzerland ) i.e. , 3 mg/m2 infusion verteporfin rationale use low dosage less collateral damaging effect retina choroid . Verteporfin infuse 10 minute follow delivery laser 692 nm 15 minute commencement infusion target area choroidal dilation hyperpermeability . Earlier laser application allow less drug accumulation RPE layer less drug less toxicity RPE . A total light energy 50 J/cm2 83 second deliver area choroidal hyperperfusion observe ICGA instead angiographic leakage site show FA . Only area choroidal vascular abnormality suppose cause serous detachment involve macula consider treat . To avoid overtreatment choroidal vasculature cause choroidal ischemia , laser spot size set maximum 4,500 µm . This restriction laser spot size adequate , previous report , reverse serous macular detachment reduce choroidal extravascular leakage sub-RPE hydrostatic pressure macular area . In patient bilateral CSC , one eye recruit study , eye thicker central retinal thickness OCT chosen . After treatment , patient give protective spectacle instruct avoid strong light 3 day . Modified Photodynamic Therapy Half fluence : The Half fluence PDT protocol CSC perform use half normal duration verteporfin laser time ( Visudyne , Novartis AG , Bülach , Switzerland ) All patient receive bolus infusion 6 mg/m2 body surface area 1 minute . Patients assign treatment protocol , use fluence 25 J/cm2 . In 25-J/cm2 group , patient receive irradiance 600 mW . Depending irradiance , time photosensitization 42 second . A total light energy 25 J/cm2 42 second deliver area choroidal hyperperfusion observe ICGA instead angiographic leakage site show FA . Only area choroidal vascular abnormality suppose cause serous detachment involve macula consider treat . To avoid overtreatment choroidal vasculature cause choroidal ischemia , laser spot size set maximum 4,500 µm . This restriction laser spot size adequate , previous report , reverse serous macular detachment reduce choroidal extravascular leakage sub-RPE hydrostatic pressure macular area . In patient bilateral CSC , one eye recruit study , eye thicker central retinal thickness OCT chosen . After treatment , patient give protective spectacle instruct avoid strong light 3 day . Documentation : Patients see regular follow-up visit within 1 week day 1 , week 1 , week 4 , month 3 treatment . A standardized evaluation perform visit include best correct visual acuity accord guideline Early Treatment Diabetic Retinopathy Study ( ETDRS ) , confocal scan laser fluorescein angiography ( FA ) , ICGA ( Heidelberg Engineering , Dossenheim , Germany ) , fundus photography , complete eye examination . Selected patient imaged optical coherence tomography ( OCT ) . The main outcome measure choroidal perfusion change , document early late ICGA . A PDT-induced increase collateral leakage area see late FA 1 day PDT define secondary outcome , primary CNV closure document early FA . Best-corrected visual acuity document safety evaluation . Data statistically analyze Wilcoxon signed-rank Wilcoxon rank sum test . Statistical significance define P &lt; 0.05 . Procedures Evaluation : The Image J , ( software ; NIH , USA ) , image software develop analysis visualization image obtain grayscale photograph , use forplanimetric evaluation area hypofluorescence detect ICGA area PDT-induced leakage see FA . Choriocapillary hypoperfusion nonperfusion grade accord scale . Angiographies evaluate two masked reader , planimetricand grade result reader average . Follow-Up Examinations : Patients assess baseline follow day 1 , 7 , 30 , 90 180 PDT . At baseline post-PDT visit , BCVA measure certified optometrist Early Treatment Diabetic Retinopathy Study ( ETDRS ) logarithm minimum angle resolution ( logMAR ) chart 4 Snellen chart 6 convert logMAR equivalent analysis . OCT recording perform use OCT 3 machine ( StratusOCT , Carl Zeiss Meditec Inc. , Dublin , CA ) . Both vertical horizontal scan 6.0 mm center fovea obtain measurement central foveal thickness . OCT central foveal thickness measure manually use retinal thickness mode define distance inner surface RPE inner surface neurosensory retina fovea . FA ICGA perform patient baseline , month 1 , 3 PDT . Additional FA ICGA carry patient persistence recurrence CSC follow-up period . CSC classify accord FA finding two group : 1 ) chronic CSC serous retinal detachment focal leakage ( Group 1 ) ; 2 ) chronic CSC diffuse leakage RPE transmission defect early phase diffuse angiographic leakage mid late phase ( Group 2 ) . Features CSC ICGA delineate accord original description . Data Analysis : The main outcome measure study include serial change logMAR BCVA OCT central foveal thickness . Other outcome measure include complication FA ICGA change follow-up period . Serial comparison mean logMAR BCVA OCT central foveal thickness perform use nonparametric Wilcoxon-signed rank test two-tailed t-test , respectively . Categorical variable analyze use chi-square test Fisher exact test . Statistical analysis perform use SPSS P value &lt; =0.05 consider statistically significant .</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patients bestcorrected visual acuity ( BCVA ) 20/200 good Presence subretinal fluid ( SRF ) and/or serous pigment epithelial detachment ( PED ) involve fovea optical coherence tomography ( OCT ) Presence active angiographic leakage fluorescein angiography ( FA ) cause CSC CNV diseases Abnormal dilate choroidal vasculature feature ICGA consistent diagnosis CSC . Patients receive previous PDT focal thermal laser photocoagulation treatment CSC . Patients evidence CNV , polypoidal choroidal vasculopathy , maculopathy clinical examination , FA , ICGA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chorioretinopathy</keyword>
	<keyword>photodynamic therapy</keyword>
	<keyword>reduce fluence</keyword>
	<keyword>reduce dose</keyword>
</DOC>